Cervomed Inc. 8-K Filing
Ticker: CRVO · Form: 8-K · Filed: Nov 4, 2025 · CIK: 1053691
| Field | Detail |
|---|---|
| Company | Cervomed Inc. (CRVO) |
| Form Type | 8-K |
| Filed Date | Nov 4, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Cervomed Inc. (ticker: CRVO) to the SEC on Nov 4, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market).
How long is this filing?
Cervomed Inc.'s 8-K filing is 2 pages with approximately 606 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 606 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-11-04 07:08:34
Key Financial Figures
- $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market
Filing Documents
- crvo20251104_8k.htm (8-K) — 31KB
- ex_882257.htm (EX-99.1) — 17KB
- 0001437749-25-032869.txt ( ) — 185KB
- crvo-20251104.xsd (EX-101.SCH) — 3KB
- crvo-20251104_def.xml (EX-101.DEF) — 12KB
- crvo-20251104_lab.xml (EX-101.LAB) — 15KB
- crvo-20251104_pre.xml (EX-101.PRE) — 12KB
- crvo20251104_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure Press Release On November 4, 2025, CervoMed Inc. (the "Company") issued a press release announcing that it had received written feedback from the U.S. Food and Drug Administration aligning on key aspects of the Company's proposed Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events The information set forth in the first paragraph, the information set forth under the heading "Phase 3 Trial Design and Regulatory Alignment," and the information set forth in the second paragraph under the heading "Advancing Towards Registration" of the Company's press release referred to in Item 7.01 above is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits The following exhibit relating to Item 7.01 is furnished and not filed: Exhibit No. Description 99.1 Press Release, issued November 4, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 4, 2025 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel